ICU Medical (ICUI) Reports Q2: Everything You Need To Know Ahead Of Earnings

ICU Medical (NASDAQ: ICUI) is set to report Q2 earnings Thursday after market close. The prior quarter revenue was $525.8 million, down 12.3% year over year, and it beat EPS estimates. For Q2, analysts expect revenue to decline about 2% year over year. The article cites an average analyst price target of $176.63 versus a $172 share price.

Original reporting
Published Aug 5, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ICU Medical (ICUI) Reports Q2: Everything You Need To Know Ahead Of Earnings — source image
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

Traders can use the stated consensus revenue decline and the company’s recent beat history to frame scenarios, but the article does not disclose new company-specific catalysts or updated estimates.

02

Market read

The main tradable element is the scheduled earnings timing for ICUI, with sentiment supported by recent price strength and a history of exceeding expectations.

03

What to watch

The piece does not discuss margins, guidance, cash flow, or specific product/regulatory drivers that typically determine post-earnings direction.

Relevance 4/10Novelty 3/10Timing: ahead of Thursday after-hours earnings

Background

Pre-earnings checklist for ICU Medical ahead of its Thursday after-market-close earnings report, referencing last quarter’s results and current consensus expectations.

Company-level read

Ticker impact

$ICUINeutralMedium confidence
Context

ICU Medical is set to report earnings this Thursday after the close, with Q2 revenue and EPS expectations discussed ahead of the print.

Expected impact

Likely elevated volatility into the earnings release, with direction dependent on whether results beat the stated revenue decline expectation.

Evidence & confidence

The only concrete company-specific facts are last quarter’s reported revenue/EPS beat and the current quarter’s consensus revenue decline; there is no new guidance, estimate change, or event beyond the scheduled earnings timing.

Market effects

Peers’ recent results (Merit Medical, Penumbra) are used as a read-across, but the article provides no new sector data beyond those cited outcomes.

None specified.

None specified.

Counterpoint

If the market is already positioned for a beat, the stock could react negatively to any modest miss versus the revenue decline expectation, even if EPS beats.

Key entities

  • ICU Medical

    NASDAQ-listed medical device company reporting earnings this Thursday after the close.

  • Merit Medical Systems

    Peer cited as having delivered Q2 revenue growth and a stock reaction after results.

  • Penumbra

    Peer cited as having reported Q2 revenues in line with consensus.

Related articles

$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ: ICUI) shares rose 10.2% after the company reported Q2 adjusted EPS of $2.37, above the $1.91 consensus, and revenue of $551.7 million, above forecasts. Free cash flow improved to $61.64 million from -$8.49 million a year earlier. ICU Medical raised full-year adjusted earnings guidance to $8.80 per share (midpoint).

$ICUIMedAI 8/10

ICU Medical (NASDAQ:ICUI) Reports Strong Q2 CY2026

ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results. Revenue rose 1.5% year over year to $551.7 million, beating Wall Street’s revenue estimate by 3.5%. Non-GAAP adjusted EPS was $2.37, up from $2.10 and 23.8% above consensus. The stock rose 1.4% to $168.02 after the release.

$SHOPMedAI 8/10

Shopify Was Supposed to Be an AI Casualty. Its AI-Referred Traffic Just Tripled.

Shopify (SHOP) reported Q2 results, citing AI-referred traffic to merchants’ storefronts that tripled year over year and orders that began with AI search also tripled. New buyers from AI channels placed orders at nearly twice the rate of other channels. Revenue rose 34% to $3.6B, GMV reached $115.6B, operating income rose 68% to $488M, and free cash flow was $654M.

$GPRKMed

Geopark Q2 Earnings Call Highlights

Geopark (NYSE:GPRK) reported Q2 earnings call updates. It plans $40m to $50m of Vaca Muerta investment in 2H 2026 after $55m in 1H, with 70% to 80% in Q3. Full-year lifting costs are guided at $17 to $19/bbl. Cash rose to $316m, net leverage fell to 1.2x EBITDA, and a $0.023/share quarterly dividend was declared.